Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
Amy Emerson, the CEO of Lykos Therapeutics, has stepped down from her role at the company, the WSJ reported.
This announcement comes nearly a month after the Food and Drug Administration (FDA) rejected Lykos’s application for its ecstasy-based therapy intended to treat post-traumatic stress disorder (PTSD).
See Also: FDA Rejects MDMA For PTSD Treatment, Calls For More Research On Psychedelic Therapy
The company, which had sought approval for its midomafetamine therapy – commonly known as MDMA or Ecstasy – was informed last month that the FDA found insufficient evidence to support the treatment’s safety and efficacy.
Leadership Change Amidst FDA Rejection
Effective immediately, Michael Mullette, the company’s chief operating officer for the past two years, will take over as interim …